# Memo Therapeutics

**Canonical:** https://apis.io/providers/memo-therapeutics/  
**Website:** https://memo-therapeutics.com/  
**APIs profiled:** 9

Memo Therapeutics AG ("MTx"), an Ipsen company, is a late-stage biotechnology company headquartered at Wagistrasse 27 in Schlieren / Zurich, Switzerland, with a US office as Memo Therapeutics US, Inc. in Wilson, North Carolina. It develops best-in-class therapeutic antibodies to transform the lives of patients with viral infections and cancer, built on DROPZYLLA, a microfluidic single-cell platform that makes a recombinant in vitro copy of an individual donor's B-cell antibody repertoire, banks it as a library, and screens it functionally at high throughput. Its lead program, potravitug, is a first-in-class monoclonal antibody against BK polyomavirus (BKPyV) reactivation in kidney transplant recipients; the Phase II SAFE KIDNEY II trial reported biopsy-proven resolution of BKPyV-associated nephropathy with sustained viral-load reduction to week 38, and the asset holds EU orphan designation. In February 2026 the company entered a collaboration and option agreement with CSL for its recombinant polyclonal IgG technology carrying milestones of up to CHF 265 million, and it has run an oncology antibody-discovery collaboration with Ono Pharmaceutical since 2022 alongside nephrology collaborations with the University Hospital of Zurich and the University Hospital of Bern. Ipsen completed its acquisition of Memo Therapeutics AG on 22 July 2026, adding potravitug to Ipsen's rare-disease pipeline. Memo Therapeutics runs no developer program and publishes no product API, developer portal, SDK or API documentation. The only machine-readable surface reachable without credentials is the WordPress REST content API behind memo-therapeutics.com, catalogued here, together with an llms.txt the site's SEO plugin publishes.

## Kin Score — 32.3 / 100 (thin)

Scored 2026-09-02 under rubric 0.18.0. Trend: flat (+0.0 from 32.3).

| Facet | Score |
|---|---|
| Discoverability | 81.5 |
| Contract Quality | 52.4 |
| Governance | 18.2 |
| Contract Governance | 18.2 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 13.7 |
| Commercial Clarity | 21.1 |
| Access Clarity | 21.1 |

Regulatory layer — **Health**: 31.3 (matched via tags).

## Agent readiness — 21.8 (agent-aware)

| Dimension | Value |
|---|---|
| Spec Presence | yes |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | bearer |
| Idempotency | no |
| Error Semantics | documented |
| OpenAPI Examples | no |
| Rate Limit Signal | documented |
| Event Surface Described | no |
| Agent Skills | derived |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |

## Access

Self-serve signup — onboarding: self-serve, pricing: unknown, trial: no (confidence: medium).

## APIs (9)

- **Memo Therapeutics Posts API** — News archive — press releases, Q&A interviews, event listings and scientific presentations (36 published on 2026-08-25).
- **Memo Therapeutics Pages API** — Corporate pages — About us, BKV, Contact us, Latest News, Further Information, Expanded Access Policy, and the privacy, cookie and terms documents (10 published on 2026-08-25).
- **Memo Therapeutics Media API** — Media library — corporate imagery, partner and investor logos and leadership portraits (163 attachments on 2026-08-25).
- **Memo Therapeutics Taxonomy API** — Categories and tags. Eight categories are registered and populated; the post_tag taxonomy is registered but empty.
- **Memo Therapeutics Comments API** — Comment collection. Registered and anonymously reachable, but empty — no post on this deployment carries comments.
- **Memo Therapeutics Search API** — Cross-content search across published objects (154 searchable objects on 2026-08-25).
- **Memo Therapeutics Discovery API** — Route, namespace, type, taxonomy and status discovery documents — the machine-readable index this profile was derived from.
- **Memo Therapeutics oEmbed API** — oEmbed 1.0 provider endpoint for memo-therapeutics.com URLs.
- **Memo Therapeutics Navigation API** — Block-theme navigation menus exposed as a post type (1 published on 2026-08-25).

## Security (2)

- **Memo Therapeutics Authentication** — 3 schemes
- **Memo Therapeutics Domain Security** — TLSv1.3 · DMARC

## Plans (1)

- **Memo Therapeutics Plans Pricing**

## Tags

Company, Biotechnology, Pharmaceuticals, Antibody Therapeutics, Rare Disease, Nephrology, transplantation, virology, Oncology, Clinical Trials, Life Sciences, Switzerland, content-api

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/memo-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.